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The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway has been identified as an important
pathway in renal cell carcinoma (RCC). We have reported a nonsense mutation in PIK3R1, which encodes
the regulatory subunit of PI3K, in a metastatic RCC (mRCC), while the mutation was absent in the
corresponding primary RCC (pRCC). To identify the function of PIK3R1 in RCC, we examined its
expression in normal kidney, pRCC and mRCC by immunohistochemistry and real-time polymerase chain
reaction. The expression of PIK3R1 significantly decreased in pRCC and was further reduced in mRCC
compared with normal tissue. Besides, its expression levels were negatively correlated with T-category of
tumor stage. Additionally, 786-O and A-704 cells with PIK3R1 depletion introduced by CRISPR/Cas9
system displayed enhanced proliferation, migration and epithelial-mesenchymal transition (EMT), and
acquired a stem-like phenotype. Moreover, the PIK3R1 depletion promoted the phosphorylation of AKT in
the cells. The knockdown of AKT by shRNA reduced p-GSK3b and CTNNB1 expression in the cells, while
the depletion of CTNNB1 impaired stem-like phenotype of the cells. Overall, PIK3R1 down-regulation in
RCC promotes propagation, migration, EMT and stem-like phenotype in renal cancer cells through the
AKT/GSK3b/CTNNB1 pathway, and may contribute to progression and metastasis of RCC.
R
enal cell carcinoma (RCC) is one of the most lethal types of urological cancer1. Recent studies have
markedly increased the understanding of the cell molecular biology of RCC, dominated by the inactivation
of VHL in ubiquitin-mediated proteolysis pathway (UMPP) and alteration of PBRM1 involved in chro-
matin regulation2–4. The increased understanding of RCC biological pathways has led to the development of
molecularly targeted therapeutic agents that have improved patient outcomes1. However, the advanced and
metastatic RCC (mRCC) remains incurable5, therefore further studies are highly needed to understand the
mechanisms of the molecular basis of resistance and response, thus leading to the discovery of novel targets
for the treatment of mRCC.
In addition to UMPP3, the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway has also been
identified as an important pathway in RCC2,6. The PI3K/AKT pathway begins with the involvement of growth
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plasma membrane and generates phosphatidylinositol-3-phosphate
(PIP3) by phosphorylating phosphatidylinositol 4, 5-bisphosphate8.
Through a pleckstrin homology domain, AKT binds to PIP3 and is
phosphorylated to pAKT8. Class IA PI3Ks are heterodimers that
consist of a catalytic subunit (p110a, p110b and p110d) and a reg-
ulatory subunit (p85a, p55a, p50a, p85b, and p55c)9. The catalytic
subunit p110a is encoded by PIK3CA, while the regulatory subunit
p85a is encoded by PIK3R19. The PI3K/AKT pathway regulates
many aspects of cellular functions, including cell growth, prolifera-
tion, translation and survival, and is also involved in pathological
conditions6. Deregulation of the pathway can lead to disturbance of
cell growth, proliferation and survival, thus resulting in growth
advantage and metastatic competence of cancer cells10.
The alteration of PI3K/AKT pathway has been found in a broad
spectrum of cancers9. Members of the pathway such as PIK3CA and
PTEN are frequently altered in RCC2. Since the pathway plays an
important role in RCC pathogenesis2, it has been showing a great
promise formolecularly targeted treatment of RCC6,9. However, only
a small number of patients benefit from single-agent PI3K targeted
therapy11. The related mechanism of unsatisfied effect of PI3K tar-
geted therapy remains to be clarified11. Can, in addition to PIK3CA
and PTEN, othermember of the pathway play a role and be a target of
therapy in RCC?
Accumulating studies have showed an important role of PIK3R1
in human carcinogenesis8,12–14. PIK3R1 has been reported as an onco-
gene in ovarian and colon tumors15, whereas it has been shown as a
tumor suppressor in hepatocellular carcinomas16. The underexpres-
sion of PIK3R1 has been reported to be associated with poor pro-
gnosis of breast cancers17. A missense mutation of PIK3R1 which
resulted in decrease of PIK3R1 expression has also been strongly
linked with colon cancers18. We have reported a nonsense mutation
in PIK3R1 in an mRCC, while the mutation was absent in the cor-
responding primary renal cell carcinoma (pRCC)14. Therefore, we
hypothesize that the downregulation of PIK3R1 may confer renal
cancer cells a selective advantage to translocate, colonize and develop
as mRCC.
We speculate that ectopic expression of PIK3R1may be associated
with progression andmetastasis of RCC. To examine our hypothesis,
we firstly analyzed the expression of PIK3R1 in RCC including both
pRCC and mRCC by immunohistochemistry (IHC) and real-time
polymerase chain reaction (RT-PCR). We discovered that the
expression of PIK3R1 in RCC negatively correlated with tumor pro-
gression and metastasis. In addition, we induced deletion mutations
ofPIK3R1 in renal cancer cell lines (786-O andA-704 cell lines) using
a CRISPR/Cas9 system to achieve haploid knockout of PIK3R1
which significantly decreased the expression of P85a. The mutated
renal cancer cells displayed increased abilities of colony formation,
tumor formation, migration, epithelial-mesenchymal transition and
oncosphere formation. Thus, our current study demonstrates that
the downregulation of PIK3R1 contributes to progression and meta-
stasis of RCC.
Results
Downregulation of PIK3R1 correlates with progression and
metastasis of RCC. In order to examine the expression of PIK3R1
in RCC, the protein expression of PIK3R1 in normal kidney (n5 13),
pRCC (n 5 13) and mRCC (n 5 21) was determined by IHC. As
shown in Fig. 1a, normal kidney tissues displayed high level of
PIK3R1 expression, whereas the expression of PIK3R1 was
decreased in pRCC and was further reduced to a lower level in
mRCC. The mRNA expression of PIK3R1 was then determined by
real-time polymerase chain reaction (RT-PCR). Compared with
normal kidney tissue group, the mRNA expression of PIK3R1 was
significantly decreased in RCC group (n 5 18) (Fig. 1b). The
epithelial-mesenchymal transition (EMT) is considered to be cru-
cial to tumor progression and metastasis, in which NCAD is the
hallmark of EMT19,20. To determine whether the downregulation of
PIK3R1 could affect the expression of NCAD, the mRNA expression
of NCAD was examined, and data showed that the expression of
NCAD had a negative correlation with the mRNA expression of
PIK3R1 (Correlation 5 0.6929, P 5 0.0014) (Fig. 1c). Addi-
tionally, the mRNA expression of PIK3R1 negatively correlated
with the T category of tumor, although there was no significant
difference among different grades (Fig. 1d). These data suggest that
the downregulation of PIK3R1 in RCCs correlates with their pro-
gression and metastasis.
Haploid knockout of PIK3R1 by CRISPR/Cas9 promotes tumor
proliferation. In order to reveal the functional influence of PIK3R1
depletion, a CRISPR/Cas9 strategy which was designed according to
the nonsensemutation reported previously14, was applied to induce a
haploid deletion mutation in order to achieve haploid knockout of
PIK3R1. Firstly, we analyzed the expression levels of PIK3R1 in
normal renal cell line (HK2) and RCC cell lines (786-O, A-498, A-
704, and ACHN) by using RT-PCR. 786-O and A-704 cell lines
showed higher expression of PIK3R1 compared with that of HK2
cell line (Supplementary Fig. 1). Therefore, we performed depletion
of PIK3R1 in 786-O and A-704 cell lines. We also confirmed the
sequence character of chr5: 67576819 in PIK3R1 in 786-O and A-
704 cell lines with Sanger sequencing. The 786-O andA-704 cell lines
harbored the wild type (WT) sequence of chr5: 67576819C in
PIK3R1 (Fig. 2a).
We then applied the CRISPR/Cas9 technology21 to screen 786-O
cells andA-704 cells with haploid deletionmutation of PIK3R1. After
Sanger sequencing validation, we obtained muted 786-O cells (786-
mut1 and 786-mut2) and A-704 cells (A-704-mut1 and A-704-
mut2) with haploid deletion mutation (Fig. 2a). To determine the
knockout efficiency in the 786 andA-704mutated cells, RT-PCR and
western blot (WB)were carried out to examine PIK3R1 expression in
786-O WT cells (786-O), mutated 786-O cells, A-704 WT cells (A-
704), andmutatedA-704 cells. ThemRNAexpression of PIK3R1was
significantly decreased in 786 and A-704 mutated cells compared
with 786-O and A-704 WT cells (Fig. 2b). The protein levels of
PIK3R1 were also significantly decreased in 786 and A-704 mutated
cells respectively (P , 0.01; P , 0.01) (Fig. 2b).
To determine the effects of haploid knockout of PIK3R1 on the
growth of renal cancer cells, we carried out colony formation assays
for the wild type and mutant cells. 786 and A-704 mutated cells
displayed enhanced colony formation capability under the condition
of separated single cells than that of 786-O and A-704 WT cells
(Fig. 2c). In order to evaluate the tumor formation capability of the
WT and muted cells, they were respectively inoculated subcuta-
neously into NOD/SCID mice to carry out tumor formation assays.
The mutated cells formed bigger tumors than those of the wild type
cells in NOD/SCID mice (Fig. 2d).
Haploid knockout of PIK3R1 promotes renal cancer cells
migration and EMT in vitro. To confirm the effects of haploid
knockout of PIK3R1 on the migration of renal cancer cells, wound-
healing and transwell assays for 786-O, 786-mut1, 786-mut2, A-704,
A-704-mut1, and A-704-mut2 cells were carried out. Eighteen hours
after artificial wounding, 786-O and A-704 WT cells demonstrated
slight migration, whereas 786 and A-704 mutated cells showed
enhanced migration ability and healed more than half of the
wound (Fig. 3a). The 786 and A-704 mutated cells showed higher
ability of migration in the transwell assay than that of 786-O and A-
704 WT cells (Fig. 3b).
Additionally, 786 and A-704 mutated cells displayed a mesench-
ymal morphology21 that was different from the epithelial morpho-
logy of 786-O and A-704 WT cells, indicating that 786 and A-704
mutated cells might undergo EMT (Fig. 3c). In the wild type and
mutant cells, the expression of EMT related gene was detected by RT-
PCR and WB20. We found that, compared with 786-O and A-704
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8997 | DOI: 10.1038/srep08997 2
WT cells, in 786 and A-704mutated cells with the downregulation of
PIK3R1, the mRNA expression of ECADwas decreased, whereas the
mRNA expression of NCAD, VIM and ZEB1was increased (Fig. 3d).
These observed changes were also found in the protein levels of
ECAD (P , 0.01; P , 0.01), NCAD (P , 0.001; P , 0.05), VIM
(P, 0.01; P, 0.05) and ZEB1 (P, 0.05; P, 0.05) in 786 andA-704
mutated cells respectively (Fig. 3d). However, no differences of CD44
and POU5F1 were observed between the wild type and mutant cells
(Fig. 3d).
In order to confirm the function of PIK3R1 in renal cancer cells,
we analyzed the expression of ECAD, NCAD, VIM, SNAIL, and
TWIST in normal renal cell (HK2) and RCC cell lines (786-O,
A498, A704, and ACHN) with RT-PCR. ACHN cell line showed
higher expression of NCAD and VIM, compared to HK2 cell line
(Supplementary Fig. 1). Therefore, we performed overexpression of
PIK3R1 in ACHN cells. Compared with ACHN-vec cells, themRNA
expression of PIK3R1 and ECAD was increased in ACHN-PIK3R1
cells, whereas the expression of NCAD, VIM and ZEB1 was de-
creased (Supplementary Fig. 3a). These changes were also observed
in the protein levels of PIK3R1 (P, 0.01), ECAD (P, 0.05), NCAD
(P, 0.01), VIM (P, 0.05), and ZEB1 (P, 0.05) in ACHN-PIK3R1
cells (Supplementary Fig. 3b). In addition, ACHN-PIK3R1 cells dis-
played a epithelial morphology21 that was different from the
mesenchymal morphology of ACHN-vec cells (Supplementary Fig.
3c). These results indicated that ACHN-PIK3R1 cells might undergo
mesenchymal-epithelial transition (MET). Taken together, PIK3R1
negatively regulated renal cancer cell migration and EMT in vitro.
Haploid knockout of PIK3R1 promotes a cancer stem cell pheno-
type. Cancer stem cells (CSCs) are defined as a subpopulation in
tumors which harbors selfrenew, differentiation and serial tumor
formation ability22. Cancer cell lines contain cancer stem-like cells
which can form cell spheres under sphere-forming conditions23. To
evaluate whether the reduction of PIK3R1 influences the cancer stem
cell phenotype of renal cancer cells, cell sphere formation assays of
786-O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2
cells were performed. After two weeks of cultivation, 786 and A-704
mutated cells developed more and bigger spheres than that of 786-O
and A-704WT cells under the medium supplemented with 20 ng/mL
EGF, FGF, N2, and B27 (Fig. 4a). CSCs have been identified based on
expression of various markers such as CD44, CD133 and CXCR424–26.
By using anti-CD44 antibodies, anti-CD133 antibodies and anti-
CXCR4 antibodies we observed that 786 and A-704 mutated cells
comprised more CD441, CD1331 and CXCR41 subset, respectively,
compared with 786-O and A-704 WT cells (Fig. 4b).
The gold standard assay to assess CSCs potential is the trans-
plantation of limiting dilutions of highly purified prospectively iden-
tified cancer cell populations into immunodeficient mice to assess
their ability to form tumors27,28. Transplantation of different dilu-
tions of the wild type cells and PIK3R1mutated cells showed that the
mutated cells had a much greater ability to initiate tumors and in-
creasing percentage of CSCs compared with the WT cells (Fig. 4c).
Haploid knockout of PIK3R1 activates WNT/b-catenin pathway
dependent on the phosphorylation of AKT. In order to uncover the
Figure 1 | Downregulation of PIK3R1 correlates with progression and metastasis in RCCs. (a), The representative immunohistochemistry
photographs of PIK3R1 expression in normal kidney tissues (n 5 13), pRCCs (n 5 13) and mRCCs (n 5 21). Scale bar 5 25 mm. (b), PIK3R1 mRNA
levels in the pairs of pRCCs and corresponding normal renal tissues (n 5 18). (c), PIK3R1mRNA expression is negatively correlated with NCADmRNA
expression across a cohort of the pairs of normal renal tissues and pRCCs (n 5 18). (d), PIK3R1mRNA expression in pRCCs according to T category and
grade. The TNM cancer staging system was designed to gauge the extent of cancer in a patient’s body. T describes the size of the tumor and whether it has
invaded nearby tissue, N describes regional lymph nodes that are involved, and M describes distant metastasis (spread of cancer from one body part to
another). Grading classification for RCC was based on the Fuhrman grading system. Data are presented as mean 6 SD. * P , 0.05, ** P , 0.01.
www.nature.com/scientificreports
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stem cell signaling pathway activated by the downregulation of
PIK3R1, the mRNA level of CTNNB1, HES1, GLI1, and NANOG
were analyzed in 786-O, 786-mut1, 786-mut2, A-704, A-704-mut1,
and A-704-mut2 cells by RT-PCR. With the downregulation of
PIK3R1 in 786 and A-704 mutated cells, the mRNA expression of
CTNNB1 was higher than that in 786-O and A-704 WT cells
(Fig. 5a). The protein levels of CTNNB1 were also increased in 786
and A-704 mutated cells respectively (P , 0.01; P , 0.05) (Fig. 5d)
There were no significant differences in the mRNA expression of
HES1 and GLI1 between the wild type and mutated cells (Fig. 5a).
Though there were no significant differences in the NANOGmRNA
expression between 786-O WT and 786 mutated cells, significant
difference was observed between A-704 WT and A-704 mutated
cells (Fig. 5a).
In order to determine the molecular mechanism underlying b-
catenin (CTNNB1) activation mediated by PIK3R1 depletion, immu-
Figure 2 | Haploid knockout of PIK3R1 promotes tumor proliferation. (a), The Sanger sequencing of PCR product including chr5: 67576819C in
786-O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2 cells. Arrowhead indicates chr5: 67576819C. (b), The RT-PCR and WB analysis of
PIK3R1 expression in 786-O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2 cells. b-actin served as control. (c), The colony formation assay
of 786-O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2 cells. Colonies were stained with crystal violet and measured after two weeks
cultivation. (d), The tumor formation assays of 786-O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2 cells. Scale bar 5 50 mm. * P, 0.05,
** P , 0.01.
www.nature.com/scientificreports
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Figure 3 | Haploid knockout of PIK3R1 promotesmigration andEMT in renal cancer cells. (a), Thewound healing analysis of in 786-O, 786-mut1, 786-
mut2, A-704, A-704-mut1, and A-704-mut2 cells. Migration rates were calculated by healing area/wound area. Scale bar 5 50 mm. (b), Transwell of
migration assays were applied to in 786-O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2 cells. Scale bar 5 25 mm. (c), Representative
pictures of in 786-O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2 cells. Scale bar 5 25 mm. (d), The RT-PCR analysis of PIK3R1, ECAD,
NCAD, VIM, ZEB1, CD44, and POU5F1 in 786-O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2 cells. TheWB analysis of ECAD, NCAD,
VIM, and ZEB1 expression in 786-O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2 cells. b-actin was applied as loading control. Data are
expressed as mean 6 SD. * P , 0.05, ** P , 0.01.
www.nature.com/scientificreports
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noprecipitation with PIK3R1 antibody was carried out by using
lysates of 786-O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-
704-mut2 cells. The quantity of p110a immunoprecipitated by
PIK3R1 was decreased due to knockout of PIK3R1 in 786 and A-
704mutated cells respectively, compared with 786-O and A-704WT
cells (P , 0.05; P , 0.05) (Fig. 5b). Additionally, more AKT was
Figure 4 | Haploid knockout of PIK3R1 promotes cancer stem cell phenotype through activating CTNNB1. (a), The representative photographs of cell
spheres formed by 786-O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2 cells. Spheres were calculated after two weeks cultivation at five
independent fields/well. Scale bar5 50 mm. (b), 786-O andA-704WT cells comprise fewer CD441, CD1331, andCXCR41 subset, respectively, compared
with 786-O andA-704WT cells. (c), The percentage of tumor-freemice 1month after the subcutaneous injection of the different dilutions of 786-O, 786-
mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2 cells into immunodeficient mice. The estimated percentage of renal cancer stem cells (RCSCs) in
786-O WT, 786-O Mut, A-704 WT, and A-704 Mut after the first transplantation using the extreme limiting dilution analysis. * P, 0.05, ** P, 0.01.
www.nature.com/scientificreports
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Figure 5 | Haploid knockout of PIK3R1 activatesWNT/b-catenin pathway dependent on the phosphorylation of AKT. (a), The RT-PCR analysis of the
mRNA expression of PIK3R1, CTNNB1, HES1, GLI1, andNANOG in 786-O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2 cells. (b), 786-
O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2 cell lysates were immunoprecipitated by anti-PIK3R1 antibody and immunoblotted with
anti-PIK3R1 (upper panel) and anti-P110 antibody (middle panel). Whole lysates immunobotted with anti-P110 antibody (lower panel) served as
control. (c), The WB analysis of p-AKT and p-ERK in 786-O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2 cells. AKT and ERK served as
control. (d), The WB analysis of CTNNB1, p-GSK3b, GSK3b in 786-O, 786-mut1, 786-mut2, A-704, A-704-mut1, and A-704-mut2 cells. (e), The WB
analysis of AKT, pAKT, pGSK3b, GSK3b, and CTNNB1 in 786-mut1 shCtrl, 786-mut1 shAKT, A-704-mut2 sh Ctrl, and A-704-mut2 shAKT cells. The
RT-PCR analysis of AKT in 786-mut1 shCtrl, 786-mut1 shAKT, A-704-mut2 shCtrl, and A-704-mut2 shAKT cells. Data are presented as mean 6 SD.
* P , 0.05, ** P , 0.01.
www.nature.com/scientificreports
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phosphorylated in 786 and A-704mutated cells (P, 0.05; P, 0.01),
compared with 786-O and A-704 WT cells that had the amount of
unchanged AKT (P 5 0.54; P 5 0.49) (Fig. 5c). However, there was
no significant change in the quantity of ERK (P5 0.07; P5 0.45) and
ERK with phosphorylation (P 5 0.08; P 5 0.30) in 786 and A-704
mutated cells respectively (Fig. 5c).
He, K. et al reported that cancer cells acquired cancer stem-like
phenotype through alteration of the PI3K/AKT/b-catenin signal-
ing29. According to a previous study30, the phosphorylation of AKT
could activate the WNT/b-catenin pathway through phosphorylat-
ing and inhibiting GSK3b. Interestingly, more GSK3b was phos-
phorylated in 786 and A-704 mutated cells compared with 786-O
andA-704WT cells (P, 0.01; P, 0.001) (Fig. 5d). To determine the
function of AKT in the mutated cells, depletion of AKT were per-
formed in 786-mut1 and A-704-mut2 cells. After the depletion of
AKT (P, 0.001; P, 0.001), the expression of pAKT (P, 0.01; P,
0.001), p-GSK3b (P, 0.001; P, 0.001) and CTNNB1 (P, 0.001; P
, 0.05) was decreased in 786-mut1 shAKT and A-704-mut2 shAKT
cells respectively, compared with 786-mut1 shCtrl and A-704-mut2
sh Ctrl cells (Fig. 5e). Taken together, the depletion of PIK3R1 acti-
vates the WNT/b-catenin pathway dependent on the phosphoryla-
tion of AKT.
Haploid knockout of PIK3R1 promotes a cancer stem cell
phenotype through WNT/b-catenin pathway. To determine the
function of CTNNB1 in the mutated cells, depletion of CTNNB1
was performed in 786-mut1 and A-704-mut2 cells respectively.
The mRNA expression of CTNNB1 was decreased in 786-mut1
shCTNNB1 and A-704-mut2 shCTNNB1 cells, compared to 786-
mut1 and A-704-mut2 cells (Fig. 6a). The decrease of CTNNB1
protein was also observed in 786-mut1 shCTNNB1 and A-704-
mut2 shCTNNB1 cells (P , 0.01; P , 0.01) (Fig. 6a). After two
weeks of cultivation, 786-mut1 shCTNNB1 and A-704-mut2
shCTNNB1 cells developed fewer and smaller spheres than that of
786-mut1 shCtrl and A-704-mut2 shCtrl cells (Fig. 6b). By using
anti-CD44 antibodies, anti-CD133 antibodies and anti-CXCR4
antibodies, we observed that 786-mut1 shCTNNB1 and A-704-
mut2 shCTNNB1 cells comprised fewer CD441, CD1331 and
CXCR41 subset, respectively, compared with 786-mut1 shCtrl and
A-704-mut2 shCtrl cells (Fig. 6c). In order to evaluate the tumor
formation capability of 786-mut1 shCTNNB1, A-704-mut2
shCTNNB1, 786-mut1 shCtrl, and A-704-mut2 shCtrl cells, they
were respectively inoculated subcutaneously into NOD/SCID mice
to carry out tumor formation assays. 786-mut1 shCTNNB1 and A-
704-mut2 shCTNNB1 cells formed smaller tumors than those of
786-mut1 shCtrl and A-704-mut2 shCtrl cells in NOD/SCID mice
(Fig. 6d). These results indicated that the haploid knockout of
PIK3R1 enhanced the abilities of self-renewal and tumor formation
dependent on the activation of the PI3K/AKT/CTNNB1 pathway in
renal cancer cells.
Discussion
Over the past 20 years, the functional role of the PI3K/AKT pathway
in tumorigenesis has been reported by numerous studies31. Members
of the pathway such as PIK3CA, AKT and PTEN, are frequently
altered, and cause the activation of the pathway in RCC2,14. As a
regulatory subunit of PI3Ks, PIK3R1 alteration is involved in carci-
nogenesis in a variety of cancers9, whereas the alteration of PIK3R1 in
RCC has been rarely reported14. In this study, we report that PIK3R1
expression is reduced in RCC, and that the reduction of PIK3R1 can
result in EMT, enhance migration ability, and promote colony
formation, tumor formation and cancer stem cell phenotype in renal
cancer cells.
Our data showed that PIK3R1 expression was reduced in RCC,
especially in advanced and metastatic RCC, and the downregulation
of PIK3R1 correlated with advanced ormetastatic RCC. These results
are in consistence with discoveries in hepatocellular and colon can-
cers16,18, indicating that the reduction of PIK3R1 expression may
acquired tumorigenicity in RCC, and thus supporting the view that
PIK3R1 may function as a potential cancer suppressor, and that the
downregulation of PIK3R1may promote progression andmetastasis
of RCC.
We then tested the role of PIK3R1 in renal cancer cell lines. We
observed that the haploid deletion mutations of PIK3R1 by
CRISPR/Cas9 system led to the haploid knockout and downregu-
lation of PIK3R1, and generated cell lines with the insufficiency of
PIK3R1. The binding of p110a to p85a was decreased in 786 and
A704 mutated cells with the reduced expression of PIK3R1. We
also showed that the downregulation of PIK3R1 functionally acti-
vated the PI3K/AKT pathway, as evidenced by the enhanced
phosphorylation of AKT in Ser473 residue. The activation of the
pathway may be due to the combined effect of several factors. The
p85 regulatory subunit of PI3K is necessary to stabilize and recruit
p110 catalytic subunit onto cellar membrane13. However, mono-
meric p85 is in competition with p85-p110 heterodimers for bind-
ing to insulin receptor substrate-1 (IRS-1) to form a non-signaling
cytosolic protein complex32. The insufficiency of PIK3R1 express-
ion would primarily result in the reduction of monomeric p85,
which would suppress the negative regulation of IRS-1/PI3K path-
way by p85, thus leading to the hyperactivation of PI3K signaling
axis32. PIK3R1 has also been shown to have a positive regulatory
effect on tumor suppressor PTEN, which negatively regulates the
PI3K/AKT pathway16. Therefore, the downregulation of PIK3R1
leads to the inhibition of PTEN function that reduces the break-
down of PIP3, and activates the downstream of the PI3K/AKT
signaling axis16.
Our data show that the reduction of PIK3R1 expression increases
the motility and migration capacity of renal cancer cells. A growing
body of evidence indicates that the PI3K/AKT pathway is involved in
the migratory process of cells, including metastatic cancer cells33.
Activated AKT mediates cell polarity and reorganizes cytoskeleton,
thus regulates the contraction of the cellular body and facilitates the
migration of cells33. AKT-mediated phosphorylation activates com-
ponents closely related to the cellular filaments which are important
for cytoskeleton dynamics34. In our present study, the expression of
VIM was elated in cells with the downregulation of PIK3R1.
Vimentin, which is phosphorylated and protected by AKT from
degradation35, is substantially up-regulated when cells are highly
motile, especially during EMT. It can promote the migration of dif-
ferent type of cells such as cancer cells35.
Interestingly, spindle-shaped morphology of mesenchymal cells
has been observed in cells with the down-expression of PIK3R1.
EMT is conducive to the survival and spread of cancer cells36. The
activation of AKT induces EMT and contributes to migration of
squamous cell carcinoma lines37. Evidences are emerging that the
action of AKT is related with EMT-inducing transcription factor38.
The hallmarks of EMT include decreased expression of epithelial
marker, such as ECAD, and a simultaneous increased expression
of mesenchymal markers, such as NCAD, VIM, CD44, ZEB1, and
POU5F120. In our study, the expression of NCAD, VIM and ZEB1
was elated in the cells with the downregulation of PIK3R1, whereas
the expression of ECAD was decreased in these cells. The activated
AKT positively regulates the expression of NCAD33, and the inhibi-
tion of the PI3K/AKT signaling inhibits the expression of NCAD39.
N-cadherin encoded by NCAD is enriched in cellular protrusions
and plays a key role in cell migration33. Altogether, through the
activation of the PI3K/AKT pathway which phosphorylates several
cytoskeleton-regulating and EMT–activating proteins, the downre-
gulation of PIK3R1 promotes migration and EMT in renal cancer
cells.
CSCs are defined as cells which are able to produce a new tumor22,
and regarded as a source of tumor progression and metastasis22.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8997 | DOI: 10.1038/srep08997 8
Figure 6 | Haploid knockout of PIK3R1 promotes cancer stem cell phenotype through activating CTNNB1. (a), The WB and RT-PCR analysis of
CTNNB1 in 786-mut1 shCtr, 786-mut1 shCTNNB1, A-704-mut2 shCtr, and A-704-mut2 shCTNNB1 cells. (b), The representative photographs of cell
spheres formed by 786-mut1 shCtr, 786-mut1 shCTNNB1, A-704-mut2 shCtr, and A-704-mut2 shCTNNB1 cells. Scale bar 5 50 mm. (c), 786-mut1
shCTNNB1 and A-704-mut2 shCTNNB1 cells comprised fewer CD441, CD1331 and CXCR41 subset, respectively, compared with 786-mut1 shCtr and
A-704-mut2 shCtr cells. (d), The tumor formation assays of 786-mut1 shCtrl, 786-mut1 shCTNNB1, A-704-mut2 shCtrl, and A-704-mut2 shCTNNB1
cells. * P , 0.05, ** P , 0.01.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8997 | DOI: 10.1038/srep08997 9
Cancer cell lines contain cancer stem-like cells23. In our current
study, we observed that the down-expression of PIK3R1 promoted
the colony formation, cell sphere and tumor formation of renal can-
cer cells and increased the expression of CTNNB1. Our data are
consistent with the study by Zhou et al, who reported that the CSC
viability and maintenance of breast cancer stem-like cells required
the activation of the PI3K/AKT signaling axis40. It has been suggested
that the PI3K/AKT pathway is critical to maintain prostate cancers
stem-like cells41. Signaling pathways including the Hedgehog/GLI1,
WNT/CTNNB1, NANOG/OCT4, and Notch/HES1 are activated in
CSCs and contribute to the function of CSCs42. We performed RT-
PCR to reckon the expression of CTNNB1, HES1, GLI1, and
NANOG. Interestingly, no significant change was observed in the
expression of HES1, GLI1 and NANOG, whereas the expression of
CTNNB1 was markedly increased, suggesting that CTNNB1 may be
involved in increased renal cancer stem-like phenotype caused by the
down-expression of PIK3R1.
Our present study demonstrates that the downregulation of
PIK3R1 in RCC enhances stem cells expansion as a result of the
activated PI3K/AKT signaling, involving the WNT/CTNNB1 path-
way. The PI3K/AKT pathway has always been ascribed to the pro-
liferation and self-renewal of cancer stem-like cells29. However,
under certain conditions, such as ectopic gene expression, cancer
stem-like cells can also be transformed from cells lacking cancer
stem-like phenotype43. The activation of the PI3K/AKT pathway
has been reported to induce differentiated cells to transform into
highly tumorigenic and cancer stem-like cells44. In our study, after
the depletion of AKT, the expression of p-GSK3b and CTNNB1
was decreased in 786-mut1 shAKT and A-704-mut2 shAKT cells.
Therefore, in consistence with previous studies, our study suggests
that the PI3K-AKT and WNT/CTNNB1 pathways converge on
GSK3b in renal cancer cells29. The WNT/CTNNB1 signaling is
involved in regulating the various types of stem cells29. In present
study, the depletion of CTNNB1 in renal cancer cells decreased the
cancer stem-like phenotype of these cells. Activated AKT can block
the kinase activity of GSK3b by phosphorylating GSK3b30, result-
ing in the accumulation of b-catenin which transforms differen-
tiated cancer cells to cancer stem-like cells29,30. Therefore, the
PI3K/AKT and WNT/CTNNB1 pathway work together as a
PI3K/AKT/GSK3b/CTNNB1 pathway which induces differen-
tiated renal cancer cells to transform into a more cancer stem-like
cells29.
To our knowledge, this study is the first report of the functional
identification of PIK3R1 in RCC. The important discovery of our
study is that PIK3R1 is down expressed in RCC, especially in
advanced andmetastatic RCC.We observed that the downregulation
of PIK3R1 resulted in EMT, increased migration, colony formation,
cell sphere, and tumor formation in renal cancer cells, suggesting that
the reduction of PIK3R1 expression confers renal cancer cells a
selective advantage to translocate, colonize and develop as mRCC,
and that PIK3R1 may be involved in the progression and metastasis
of RCC through the PI3K/AKT/GSK3b/CTNNB1 pathway. Since
the reduction of PIK3R1 expression and activating alterations in
PIK3CA can simultaneously be involved in RCC, conformational
changes may result from these alterations. These changes would
eliminate the repression of PIK3CA caused by PIK3R132. There-
fore, the exploitation of agents that can restore the repression regu-
lation of PIK3R1 and inhibit the expression of PIK3CA,may be a new
strategy to treat RCC.
In summary, our study suggests that PIK3R1 is down-regulated in
RCC, especially in advanced and metastatic RCC. The downregula-
tion of PIK3R1 promotes EMT, migration, and cancer stem cell
phenotype in renal cancer cells and may contribute to the progres-
sion and metastasis of RCC by activating the PI3K/AKT/GSK3b/
CTNNB1 pathway. Increasing or restoring expression of PIK3R1
may be a novel treatment strategy for RCC.
Methods
Reagent and antibody. Antibodies that recognize pAKT (Ser473) (Cell Signaling
Technology, #9271), AKT (Cell Signaling Technology, #9272), pERK (Thr202/
Tyr204) (Cell Signaling Technology, #4370), ERK (Cell Signaling Technology,
#4695), p85a (Santa Cruz, sc-376112), p110a (Cell Signaling Technology, #4249), b-
actin (Sigma, A1978), NCAD (Abcam, AB98952), ECAD (Cell Signaling Technology,
#3195), VIM (RV202) (Abcam, AB8978), ZEB1 (D80D3) (Cell Signaling Technology,
#3396), pGSK3b (Ser9) (Cell Signaling Technology, #9323), GSK3b (Y174) (Abcam,
AB32391), and non-phospho CTNNB1 (Ser33/37/Thr41) (Cell Signaling
Technology, #4270) were used in the study. Horseradish peroxidase (HRP) labelled
secondary antibody (Beyotime Biotech) was used in western blots. Protein A-
Sepharose 4B beads (Invitrogen, 10-1041) was used for immunoprecipitation studies.
Patients and tissue specimens. For the protein expression of PIK3R1, the formalin-
fixed, paraffin-embedded (FFPE) tissue samples of patient-matched normal renal,
pRCC and mRCC tissues from 13 patients who underwent nephrectomy between
May 2008 andApril 2013 were obtained from the archives of the ZhujiangHospital of
the Southern Medical University (Supplementary table 1). The biopsy samples of
mRCCs from eight patients who underwent biopsies of metastases but not
nephrectomy between May 2009 and September 2013 were also collected in the
hospital (Supplementary table 1). Median age of these patients was 56 years (range:
16–71 years). Thirteen of patients were male and the rest were female. For the mRNA
expression of identified genes, pRCCs tissues and corresponding normal renal tissues
from 18 patients who underwent nephrectomy in the hospital between August 2012
and October 2013 were immediately collected following surgical resection
(Supplementary table 2). The median age of these patients was 50 years (range: 29–65
years). Thirteen of these patients were male and the others were female. The disease
stage of all patients was classified according to the American Joint Committee on
Cancer staging system45. This study was reviewed and approved by the Ethics
Committee of the Southern medical University, and was carried out according to the
World Medical Association Declaration of Helsinki. The written informed consents
were obtained from all patients or their guardians.
Immunohistochemistry. Sections (4 mm) were deparaffinized and rehydrated. After
antigen retrieval, these sections were treated with 3% H2O2 solution, incubated with
8% bovine serum albumin for 30 min and primary antibody at 4uC overnight, then
incubated with corresponding secondary antibody, and subsequently stained with
DAB kit (ZSGB Bio). The nucleus was counterstained with hematoxylin. The overall
staining for PIK3R1 was measured by the multiplication of staining percentage (0%–
100%) and staining intensity on a numerical scale (none 5 1, weak 5 2, moderate 5
3, strong 5 4), resulting in an overall product score.
Real-Time PCR analysis of PIK3R1 expression. Total RNA was extracted using
RNA isolation kit (Tiangen Biotech) and subjected to cDNA synthesis using
PrimeScript RT reagent Kit (Takara Bio). The cDNAwas then used for the evaluation
of the relative mRNA levels of the indentified gene, running in an ABI 7300 analyzer
(Applied Biosystems). SYBR Green I (Tiangen Biotech) was used as the fluorescent
probe. Primer sequences for RT-PCR are listed in the supplementary table 3. The
relative expression levels of the target genes were referred to as a housekeeping gene,
GAPDH.
Cell line.HK-2 cells were cultured in DMEM/F12 medium (Gibco). Other cells were
maintained in RPMI 1640 medium (Gibco). All mediums were supplemented with
10% fetal bovine serum (FBS) (Gibco), 100 U/mL penicillin (Gibco) and 100 mg/mL
streptomycin (Gibco), and incubated at 37uC with 5% CO2 in a humidified
atmosphere.
PIK3R1 knockout by CRISPR/Cas9. The knockout of PIK3R1 in 786-O and A-704
cell lines was achieved by CRISPR/Case9 system. One 23-base sgRNA (59-
AATGAACGACAGCCTGCACCAGG-39) was designed to the target site (g.chr5:
67576819) in the PIK3R1 (Gene ID: 5295). The U6-gRNA expression cassette
including U6 promoter and 183 bp sgRNA tails was synthesized (Invitrogen) and
inserted into pCEP4 vector (Invitrogen) by KpnI and XhoI. The sgRNA was
synthesized (Invitrogen) and inserted into two AarI site between U6 promoter and
sgRNA tails to form the pCEP4-U6-gRNA expression vector (Supplementary Figure
2). The sequence of Cas9 was consistent with previous reports46,47. The T7 promoter
was added upstream of the Cas9 sequence. All the sequences were synthesized
(Invitrogen) and ligated to the pMD-18T-CMV-MCS-BGPA by NheI/AflII to form
CMV-Cas9 expression vector (Supplementary Figure 2).
786-O and A-704 cells were transfected according to Lipo-fectamine 2000
(Invitrogen) protocol. Briefly, Cells were transfected at 60% confluency in 12 well
with 500 ng of pCEP4-U6-gRNA expression vector, 500 ng of CMV-Cas9 expression
vector and 3 mL Lipo-fectamine 2000. After G418 (500 ng/mL) selection for 10 days,
G418-resistant colonies were picked and cultured in 24 well plates. Genomic DNA
was extracted with E. Z.N.A. Tissue DNA Kit (OMEGA). Targeted cleavage was
measured by PCR amplification (forward primer: 59 CTCATCAGTATTGGC-
TTACGCTT 39 and reverse primer: 59GGTTGTTTAGACTTTCCACGGTA 39) and
T7 E1 assay. The fragments were determined by Sanger sequencing. To better verify
the mutations (insertions and deletions), the PCR product of mutated colonies was
then ligated to pMD-18T vector (Takara Bio). Individual mutation and mutational
spectra were obtained from Sanger sequence. Cell clones with haploid deletion
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mutation of PIK3R1 were selected for evaluating the function of PIK3R1 in renal
cancer cells.
Western blot and immunoprecipitation (IP). Cells were lysed with
radioimmunoprecipitation assay buffer (Beyotime Biotech). Protein was determined,
separated and transferred to polyvinylidene difluoride membranes (Pall Life
Sciences). The membranes were blocked, then probed with corresponding primary
antibody and HRP-conjugated secondary antibodies (Beyotime Biotech), and
detected using BeyoECL PLUS Kit (Beyotime Biotech).
For immunoprecipitation assays, cell lysates were incubated with the PIK3R1
antibody overnight and precipitated with protein A-Sepharose 4B beads (Invitrogen)
at 4uC for 4 h. The immunoprecipitated proteins were washed, separated on SDS-
PAGE, transferred onto a PVDF membrane, and followed by western blot analysis.
Colony formation assay. Briefly, single cells were seeded onto 6-well plates
(Corning) at a density of 1000 cells/well and then incubated at 37uC. After two weeks
of culture, colonies were stained with 0.5% crystal violet solution for 30 min at room
temperature. The colonies from three replicate wells were counted, and pictures were
captured digitally.
Generation of xenografts. For generation of xenografts, different dilutions of cells
were injected withMatrigel (BD Biosciences) subcutaneously into the backs of NOD/
SCIDmice. The volume of xenografts was seriallymeasured. Themice were sacrificed
after 30 days. Animal work was carried out in compliance with the ethical regulations
approved by the Animal Care Committee, Southern medical University.
Wound healing assay. Briefly, 4 3 105 cells were seeded into a 24 well plate. After
overnight incubation, monolayer cells grew to confluency. Artificial wounds were
introduced with the P200 pipette tip. The pictures of the wounded area were taken
immediately (time 0 h), and at 18 h with an inverted microscope (Olympus Corp).
The whole assay was repeated three times.
Transwell Assay. Cells were respectively harvested, suspended and added to the
upper compartment of transwell inserts (8 mm pore size; Corning). The lower
chambers were filled with RPMI-1640 supplemented with 10% FBS. After incubation
for 16 hr, cells that had notmigrated from the upper chamber were scraped away. The
cells that migrated to the lower surface of each membrane were stained and counted
under a light microscope in in five fields/well. The whole assay was repeated three
times.
Spheres Culture. Single cells were seeded at a density of 5 3 103 cells/well in 6-well
plates with ultra-low attachment surface (Corning). Cells were maintained in serum-
free 1:1 DMEM/F12 (Gibco) supplemented with 20 ng/mL EGF (Invitrogen), 20 ng/
mL bFGF (Invitrogen), 2% B27 (Invitrogen), 1% N2 (Invitrogen), and 100 mg/mL
streptomycin (Gibco). The number of tumor spheres was counted 14 days after
seeding. The whole assay was repeated three times.
Cell labeling and flow cytometry analyzing. Cells were harvested and washed twice
in ice-cold PBS. Then cancer cells were stained with FITC-conjugated anti-CD133
antibody, PE-conjugated anti-CD44 antibody and FITC-conjugated anti-CXCR4
antibody, respectively, for 30 min on ice. After washing with PBS, the labeled cells
were analyzed by flow cytometry (BD FACSAria III).
Knockdown of AKT and CTNNB1 with shRNA. Four shRNA targeted against the
different regions of AKT and CTNNB1 and scrambled shRNAs were designed,




CATCAT TCTTGAGGTTTTTg; shAKT Ctrl: CcggAGTTCCAGTACGGCT-
CCAACTCGAGTT GGAGCCGTACTGGAACT TTTTTg. The resulting lentiviral
vectors containing the CTNNB1 and AKT shRNA were named shCTNNB1 and
shAKT lentivirus. Cells were transfected with the shCTNNB1 and shAKT lentivirus
to obtain cell lines stably expressing the CTNNB1 and AKT shRNA.
Overexpression of PIK3R1. PIK3R1 (NM_181523.2) was amplified by PCR with the
following primers (forward: 5’- CGG AAT TCC ATG CAT GGT GAT TAT ACT
CTTACA -3’ and reverse: 5’- CGCGGA TCC TCA TCGCCT CTG CTG TGCATA
TAC -3’). The PCR product was purified and cloned into pSin-GFP-vector to obtain
Psin-GFP-PIK3R1. ACHN cells were transfected with the pSin-GFP-PIK3R1
lentivirus to obtain a cell line stably expressing the PIK3R1 cDNA.
Statistical analysis. Student’s t-test was used to comparing themeans of two samples.
Linear correlation analysis was used to determine relationship between PIK3R1 and
NCAD mRNA expression. A value of p less than 0.05 (* P, 0.05, ** P, 0.01) was
regarded statistically significant.
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